ESR1 and breast carcinoma: In recent years, ER + HER2− breast cancers have been determined by Oncotype Dx RS as an indication for chemotherapy based on the risk of recurrence [24]; therefore, collaboration with Oncotype Dx was also evaluated in terms of its clinical utility value.